In metastatic pancreatic cancer, patients can be treated upfront with either FOLFIRINOX or gemcitabine combined with nab-paclitaxel (Abraxane). Results of the phase III MPACT study showed that gemcitabine/nab-paclitaxel improved progression-free and overall survival (OS) compared with gemcitabine alone (HR, 0.69; 95% CI, 0.58-0.82; P <.001) in patients with metastatic pancreatic cancer with a Karnofsky performance score ≥70.1 Median OS was 8.5 months and 6.7 months, respectively, in the combination and single-agent gemcitabine arms. Read more . . .
An emergence of new treatment options has revitalized the outlook for patients with metastatic pancreatic cancer and advanced hepatocellular carcinoma (HCC), but the next set of unanswered questions includes the role of immunotherapy and establishing second-line standards of care, respectively, said Jimmy J. Hwang, MD.